Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
George Siber
AddedMar 31, 2024
UpdatedMay 31, 2026
George Siber

George Siber

Board Member, Selecta Biosciences

CrunchbaseLinkedIn

George Siber's Career

Selecta Biosciences
Selecta Biosciences

Watertown, MA, US

Board Member· Board
Genocea Biosciences
Genocea Biosciences

Cambridge, MA, US

Board Member· Board
Affinivax
Affinivax

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

George Siber's Career

Selecta Biosciences
Selecta Biosciences
Public$380.5M752008Watertown, MA, US
Board Member· Board

Leadership at Selecta Biosciences

Aymeric SallinAymeric SallinBoard Member
Omid FarokhzadOmid FarokhzadFounder

Similar to Selecta Biosciences

Cleveland BioLabsCleveland BioLabsFort Collins, CO, USImmunotherapiesest. 2003Cleveland BioLabsFort Collins, CO, US · est. 2003

Biotech research agency restoring immune health through safe drugs.

Public · $137.2M75
ImunonImunonLawrenceville, NJ, USBiotech, Treatmentsest. 2000ImunonLawrenceville, NJ, US · est. 2000

IMUNON, Inc., a US-based clinical stage biotech company, innovates safe and effective treatments for a broad array of diseases.

Public · $113.8M27
NantkwestNantkwestCulver City, CA, USCancer Treatment, Immunotherapyest. 2014NantkwestCulver City, CA, US · est. 2014

ImmunityBio, Inc.: A US-based biotech firm specializing in immunotherapy for cancer and infectious diseases.

Public · $103.5M51
MacroGenicsMacroGenicsRockville, MD, USest. 2000MacroGenicsRockville, MD, US · est. 2000

US-based MacroGenics, Inc. develops novel biologics for cancer, autoimmune disorders, and infectious diseases.

Public · $165.9M357
Genocea Biosciences
Genocea Biosciences
Acquired$507.7M02006Cambridge, MA, US
Board Member· Board

Leadership at Genocea Biosciences

Chip ClarkChip ClarkBoard Member
Ken BateKen BateBoard Member
Affinivax
Affinivax
Acquired$377.5M02014Cambridge, MA, US
Board Member· Board

Leadership at Affinivax

Bob MoreBob MoreBoard Member
Steven M. AltschulerSteven M. AltschulerBoard Member
Kamran TavangarKamran TavangarCo-Founder
Richard MalleyRichard MalleyBoard Member
Fran HellerFran HellerBoard Member
Steve BruggerSteve BruggerCEO

George Siber's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailHiroshi MikitaniHiroshi MikitaniBoard Member · RakutenKen KutaragiKen KutaragiBoard Member · RakutenTakashi MitachiTakashi MitachiBoard Member · Rakuten

People Similar to George Siber

Jeffrey BluestoneJeffrey BluestoneBoard Member · Parker Institute for Cancer ImmunotherapyAlejandro BerlinAlejandro BerlinBoard Member · VaccinexGeoffrey RubinGeoffrey RubinCo-Founder · Informatics In ContextJustin StebbingJustin StebbingBoard Member · NightHawk BiosciencesJoel DudleyJoel DudleyBoard Member · Harmonic DiscoveryMichael SerioMichael SerioBoard Member · Image Insight